Comparison between oral dydrogesterone versus micronized vaginal progesterone gel in clinical outcome within the first HRT-FET cycle: a retrospective analysis.

Autor: Ye TM; Center of Reproductive Medicine, The University of Hong Kong-Shenzhen Hospital, No.1, Haiyuan Road, Shenzhen City, Guangdong Province, The People's Republic of China. yetm@hku-szh.org.; Center of Reproductive Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200233, China. yetm@hku-szh.org., Luo LD; Center of Reproductive Medicine, The University of Hong Kong-Shenzhen Hospital, No.1, Haiyuan Road, Shenzhen City, Guangdong Province, The People's Republic of China.; Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong Province, China., Huang YF; Center of Reproductive Medicine, The University of Hong Kong-Shenzhen Hospital, No.1, Haiyuan Road, Shenzhen City, Guangdong Province, The People's Republic of China.; Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong Province, China., Ding S; Center of Reproductive Medicine, The University of Hong Kong-Shenzhen Hospital, No.1, Haiyuan Road, Shenzhen City, Guangdong Province, The People's Republic of China.
Jazyk: angličtina
Zdroj: Archives of gynecology and obstetrics [Arch Gynecol Obstet] 2024 May; Vol. 309 (5), pp. 2167-2173. Date of Electronic Publication: 2024 Mar 19.
DOI: 10.1007/s00404-024-07465-7
Abstrakt: Objective: The purpose of this study is to compare the clinical efficacy of oral dydrogesterone and micronized vaginal progesterone (MVP) gel during the first HRT-FET cycle.
Methods: A retrospective cohort study based on a total of 344 women undergoing their first HRT-FET cycles without Gonadotropin-Releasing Hormone agonist (GnRH-a) pretreatment was conducted. All the cycles were allocated to two groups in the reproductive medical center at the University of Hong Kong-Shenzhen Hospital. One group (n = 193) received oral dydrogesterone 30 mg/d before embryo transfer, while the other group (n = 151) received MVP gel 180 mg/d.
Results: The demographics and baseline characteristics of two groups were comparable. We found no statistically significant difference in live birth rate (24.35% vs. 31.13%, P = 0.16), clinical pregnancy rate (34.72% vs. 36.42%, P = 0.74), embryo implantation rate (25.09% vs. 28.36%, P = 0.43), positive pregnancy rate (42.49% vs 38.41%, P = 0.45), miscarriage rate (9.33% vs 3.97%, P = 0.05), or ectopic pregnancy rate (0.52% vs. 0.66%, P = 0.86) between the oral dydrogesterone group and MVP gel group. In the multivariate logistic regression analysis for covariates, medication used for luteal support was not associated with live birth rate (OR = 0.73, 95% CI: 0.32-1.57, P = 0.45). And the different luteal support medication did not have a significant positive association with the live birth rate in the cycles with day 2 embryo transferred (OR = 1.39, 95% CI:0.66-2.39, P = 0.39) and blastocyst transferred (OR = 1.31 95% CI:0.64-2.69, P = 0.46).
Conclusion: 30 mg/d oral dydrogesterone and 180 mg/d MVP gel revealed similar reproductive outcomes in HRT-FET cycles in the study.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: